TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Pfizer's Future: Biotech Follow-ups Derek Lowe submits: The Wall Street Journal has an article detailing some of Pfizer's (PFE) plans in the biologics area: stepping in with second-generation versions of current winners from other companies. New versions of Rituxan and Enbrel are in the works, with the improvements mostly coming in how often the drugs need to be given. They're not alone in this - Merck (MRK) has announced that they're going to go after the same sorts of markets. And I can see the business rationale, since the original products have been such huge successes.Complete Story » seekingalpha.com |
AHRQ and Ad Council Encourage Men to Take Preventive Steps in their Health Care - Video New Research Finds Men are 24 Percent Less Likely than Women to have Visited their Doctor; Public Service Ads Launch as part of Men's Health Week feedproxy.google.com |
Medicare Fraud Bust Yields 94 Arrests Ninety-four medical professionals around the U.S. have been charged for their alleged involvement in a scheme to submit $251 million of false claims to Medicare. online.wsj.com |
Purdue Pharma to Settle Oxycontin Claims Purdue Pharma agreed to pay $16 million to settle a lawsuit by purchasers of Oxycontin over how it obtained patents on the painkiller in the 1990s. online.wsj.com |
Private Biotechs Take Different Avenues to Rake in Cash The Burrill Report submits: By Marie DaghlianReata Pharmaceuticals is filling its coffers ahead of late stage trials with a lucrative deal for its mid-stage treatment for chronic kidney disease. The private Irving, Texas-based biopharma is granting Abbott Laboratories (ABT) exclusive rights to develop and commercialize bardoxolone outside the United States, excluding certain Asian markets. In return, Reata will receive $450 million in upfront and near-term payments, and a minority equity investment in the company. Complete Story » seekingalpha.com |